VC-5321October 9, 2026 · 2 min

FDA Approves Novartis' Rhapsido as First Pill for Symptomatic Dermographism

Novartis' Rhapsido (remibrutinib) won FDA approval as the first treatment for symptomatic dermographism. The BTK inhibitor showed 29.3% complete response vs 14…